231 related articles for article (PubMed ID: 34482090)
21. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
[TBL] [Abstract][Full Text] [Related]
22. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
23. DemographIc Assessment and EValuation of DEgree of Lipid Control in High Risk Indian DySlipidemia PatiEnts (DIVERSE Study).
Malhotra N; Keshan MK; Agarwal A; Kumar RA; Trailokya A; Dalvi K; Talele S
J Assoc Physicians India; 2016 Apr; 64(4):38-46. PubMed ID: 27734640
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).
Devroey D; Radermecker RP; Van der Schueren BJ; Torbeyns B; Jaken RJ
Int J Clin Pract; 2014 Feb; 68(2):180-7. PubMed ID: 24308644
[TBL] [Abstract][Full Text] [Related]
25. Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan - A Retrospective Database Analysis.
Umeda T; Hayashi A; Harada A; Okuyama K; Baxter CA; Tokita S; Teramoto T
Circ J; 2018 May; 82(6):1605-1613. PubMed ID: 29628458
[TBL] [Abstract][Full Text] [Related]
26. Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey.
Koskinas KC; Catapano AL; Baigent C; Tokgozoglu L; Mach F
Eur J Prev Cardiol; 2022 Feb; 28(18):2030-2037. PubMed ID: 33580792
[TBL] [Abstract][Full Text] [Related]
27. Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias.
Vrablík M; Šarkanová I; Breciková K; Šedová P; Šatný M; Tichopád A
PLoS One; 2023; 18(5):e0272883. PubMed ID: 37216363
[TBL] [Abstract][Full Text] [Related]
28. Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study.
Gavina C; Seabra-Carvalho D; Aguiar C; Anastassopoulou A; Teixeira C; Ruivo JA; Almeida É; Luz-Duarte L; Corte-Real A; Canelas-Pais M; Taveira-Gomes T
Clin Cardiol; 2024 Jan; 47(1):e24183. PubMed ID: 37933175
[TBL] [Abstract][Full Text] [Related]
29. How Did the Updated 2019 European Society of Cardiology/European Atherosclerosis Society Risk Categorization for Patients with Diabetes Affect the Risk Perception and Lipid Goals? A Simulated Analysis of Real-life Data from EPHESUS Study.
Başaran Ö; Doğan V; Mert KU; Özlek B; Özlek E; Çelik O; Çil C; Özdemir İH; Rencüzoğulları İ; Özpamuk Karadeniz F; Tekinalp M; Aşkın L; Demirelli S; Gencer E; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Çinier G; Halil Akay K; Pekel N; Mert GÖ; Şenol U; Demir V; İnci S; Derviş E; Biteker M; Kayıkçıoğlu M
Anatol J Cardiol; 2023 Feb; 27(2):78-87. PubMed ID: 36747449
[TBL] [Abstract][Full Text] [Related]
30. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
[TBL] [Abstract][Full Text] [Related]
31. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
[TBL] [Abstract][Full Text] [Related]
32. Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study.
Brandts J; Bray S; Villa G; Catapano AL; Poulter NR; Vallejo-Vaz AJ; Ray KK;
Lancet Reg Health Eur; 2023 Aug; 31():100665. PubMed ID: 37547279
[TBL] [Abstract][Full Text] [Related]
33. [Treatment and LDL cholesterol adjustment in patients with high and very high cardiovascular risk in Germany compared with Europe - data from the SANTORINI registry].
Stürzebecher PE; Tünnemann-Tarr A; Tuppatsch K; Laufs U
Dtsch Med Wochenschr; 2023 Apr; 148(9):55-64. PubMed ID: 36858065
[TBL] [Abstract][Full Text] [Related]
34. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.
De Luca L; Arca M; Temporelli PL; Meessen J; Riccio C; Bonomo P; Colavita AR; Gabrielli D; Gulizia MM; Colivicchi F;
Int J Cardiol; 2020 Oct; 316():229-235. PubMed ID: 32470532
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany.
Gitt AK; Jünger C; Smolka W; Bestehorn K
Clin Res Cardiol; 2010 Nov; 99(11):723-33. PubMed ID: 20521058
[TBL] [Abstract][Full Text] [Related]
36. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
37. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
[TBL] [Abstract][Full Text] [Related]
38. Obesity, ultrasound indexes of fat depots and lipid goal attainment in patients with high and very high cardiovascular risk: A novel approach towards better risk reduction.
Haberka M; Okopień B; Gąsior Z
Nutr Metab Cardiovasc Dis; 2016 Feb; 26(2):123-33. PubMed ID: 26830392
[TBL] [Abstract][Full Text] [Related]
39. The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study.
Blom DJ; Santos RD; Daclin V; Mercier F; Ruiz AJ; Danchin N;
Eur J Prev Cardiol; 2020 Sep; 27(13):1403-1411. PubMed ID: 31533447
[TBL] [Abstract][Full Text] [Related]
40. Treatment and low-density lipoprotein cholesterol levels in patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular risk: a population-based cross-sectional study in the Netherlands.
Heintjes EM; Anastassopoulou A; Kuiper J; Bilitou A; Beest FJAP; Herings RMC; Postma MJ; Jukema JW
Curr Med Res Opin; 2023 Jan; 39(1):1-11. PubMed ID: 36168818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
